2024 ACCP Virtual Journal Club Webinar-June | Estimation of Absolute and Relative Body Fat Content Using Noninvasive Surrogates: Can DXA Be Bypassed? - On Demand
-
You must log in to register
- User - Free!
- Member - Free!
2024 ACCP Virtual Journal Club Webinar: Estimation of Absolute and Relative Body Fat Content Using Noninvasive Surrogates: Can DXA Be Bypassed?
Live Session: Wednesday, June 26th, 2024, from 12:00 to 1:00 PM ET
On Demand: June 26th, 2024 to June 26th, 2027
Why is this article important to your practice?
This study explores innovative methods to predict body fat content using easily measurable anthropometric variables like age, height, weight and waist circumference instead of relying on the expensive and less accessible dual-energy x-ray absorptiometry (DXA) scanning. This research is crucial as it provides an improved and validated algorithm for predicting absolute body fat, which can enhance clinical practices related to obesity management. Understanding these new predictive methods can directly impact practice, especially considering the critical role that body composition plays in pharmacokinetics and pharmacodynamics. Efficient and accurate body fat estimation methods are essential for optimizing drug dosing and therapeutic strategies in obese patients, thereby improving treatment outcomes and patient care. Learners that complete this activity will be provided an evidence-based, validated and predictive algorithm as an alternative to DXA scanning to accurately estimate absolute body fat.
Target Audience:
Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and other health care professionals who use the assessment of body fat content in clinical trials and clinical practice.
Learning Objectives
After completing this activity, the learner will be able to:
- Describe at least one limitation to the use of DXA scanning for obesity clinical trials and/or drug development;
- Identify at least one DXA-determined measurement that was selected as a dependent (outcome) variable in this study;
- List at least one surrogate variable that was predictive of DXA-determined absolute body fat;
- Identify which surrogate variable had the greatest impact (i.e., magnitude of change) on DXA-determined total body fat in men and women utilizing standardized regression coefficient data.
David J. Greenblatt, MD
Professor
Tufts Univ School of Medicine
David J. Greenblatt, M.D.
Louis Lasagna Endowed Professor, Tufts University School of Medicine.
A native of Newton, Massachusetts, Dr. Greenblatt is a Magna Cum Laude graduate of Amherst College (1966). He graduated from Harvard Medical School in 1970, then trained in internal medicine at the Montefiore Hospital, New York City (1970-1971), and on the Harvard Medical Service at Boston City Hospital (1971-1972). Following a Fellowship in Clinical Pharmacology at Massachusetts General Hospital, under the mentorship of Dr. Jan Koch-Weser (1972-1974), he stayed on to head their Clinical Pharmacology Unit (1975-1979).
Dr. Greenblatt has been on the Faculty of Tufts University School of Medicine (TUSM) and the Staff of Tufts Medical Center (TMC) since 1979. He is a senior faculty member in the Graduate Program in Pharmacology & Drug Development, and has previously served as Chair of the Department of Pharmacology and Experimental Therapeutics at TUSM, Program Director and Associate Program Director of the institution’s Clinical/Translational Research Center, and Chair of the Institutional Review Board. He has received many awards and honors over his career, including the Distinguished Investigator Award from the American College of Clinical Pharmacology, and the Oscar B. Hunter Career Achievement Award from the American Society for Clinical Pharmacology and Therapeutics
There are no relevant financial relationships to disclose.
Joseph Ma, PharmD
Professor, Clinical Pharmacy
Univ of California San Diego, Skaggs School of Pharmacy & Pharmaceutical Sciences
Joseph D. Ma, PharmD, FCP is Professor in the Division of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences, Univ of California San Diego. He is also the faculty director of the Drug Development and Product Management Master’s Program at UC San Diego. He received his pharmacy degree from Univ of California San Francisco and completed a clinical pharmacology fellowship at Bassett Healthcare, Cooperstown, NY. His research interests are evaluating in vivo drug metabolizing enzyme activity in the context of drug-drug interactions and opioid pharmacokinetic variability. His current clinical practice is the Doris A. Howell Pain and Palliative Care Service at the Univ of California San Diego Moores Cancer Center. Under a collaborative practice agreement he is able to initiate, stop, and/or adjust therapy for the management of pain and other physical symptoms associated with cancer and/or chemotherapy.
There are no relevant financial relationships to disclose.
Key:
Complete
Next
Failed
Available
Locked